| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/17/2022 | 193.26% | Lake Street | $7 → $5 | Maintains | Buy |
| 03/30/2021 | 369.21% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
| 11/05/2020 | 193.26% | Ascendiant Capital | → $5 | Initiates Coverage On | → Buy |
| 10/13/2020 | 193.26% | Lake Street | → $5 | Initiates Coverage On | → Buy |
| 06/28/2018 | 193.26% | Maxim Group | → $5 | Initiates Coverage On | → Buy |
PAVmed Questions & Answers
The latest price target for PAVmed (NASDAQ: PAVM) was reported by Lake Street on August 17, 2022. The analyst firm set a price target for $5.00 expecting PAVM to rise to within 12 months (a possible 193.26% upside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for PAVmed (NASDAQ: PAVM) was provided by Lake Street, and PAVmed maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PAVmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PAVmed was filed on August 17, 2022 so you should expect the next rating to be made available sometime around August 17, 2023.
While ratings are subjective and will change, the latest PAVmed (PAVM) rating was a maintained with a price target of $7.00 to $5.00. The current price PAVmed (PAVM) is trading at is $1.71, which is out of the analyst's predicted range.